Podcasts about Lonza

Send us a textIs an Indian CDMO the right move for your biologics CMC development?Pulling back the curtain on what might be your next strategic manufacturing advantage, this episode reveals the hidden capabilities emerging from India that leading biotech companies are racing to access. As supply chain vulnerabilities continue to expose risks in traditional manufacturing models, could the solution lie halfway around the world?Joining us to reveal the inside story is Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions and veteran of global pharma giants like Bayer, Merck and Lonza. With over 20 years in biotech, Abdelaziz brings unique insights on when and why you might want to look beyond traditional Western manufacturing partners. Our host, David Brühlmann, leverages his 15+ years of biotech industry experience to extract the practical insights you need to make informed decisions about your manufacturing strategy.In this second segment, we'll dive deeper into the Indian CDMO and biomanufacturing landscape. Then we'll explore Lupin's specialized capabilities and finally extract Abdelaziz's most valuable leadership insight from his role as a CEO.Key insights from this episode:The One-Stop Solution Advantage: Discover how Lupin is building rare end-to-end manufacturing capabilities for complex modalities like Antibody-Drug Conjugates (ADCs) - potentially eliminating the headache of managing multiple manufacturing partners across continents.Beyond Labor Cost Advantages: "Digitalization plays a key role, especially if you are operating in a cost-competitive space," explains Abdelaziz. Learn how Indian CDMOs are strategically automating key processes to drive both efficiency and quality, challenging Western perceptions.Leadership Across Cultures: "Listen, listen, listen," emphasizes Abdelaziz when discussing cross-cultural leadership. Understand the subtle communication dynamics that can make or break a global manufacturing partnership, especially when navigating hierarchy-sensitive cultures.Whether you're actively evaluating Indian manufacturing options or simply preparing for the shifting global biotech landscape, these next several minutes deliver insights you can't afford to miss.Listen to the full episode to extract the specific capability indicators that will help you determine if and when an Indian CDMO partnership makes strategic sense for your unique biologics pipeline.Want to find out more about the CDMO selection? Here's what one of our distinguished guests had to say about it:Episodes 103-104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma MostafaConnect with Abdelaziz Toumi:LinkedIn: www.linkedin.com/in/abdelaziztoumiLupin Manufacturing Solutions: www.lupin.comNext step:Transform your process development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/callReady to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Send us a textIs an Indian CDMO the right move for your biologics pipeline?As Western biotech companies seek new strategic advantages, one question keeps surfacing: Is India truly becoming the next biotech manufacturing powerhouse? And what hidden capabilities are emerging that leading companies are racing to access?In this episode of the Smart Biotech Scientist Podcast, Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions and veteran of global pharma giants like Bayer, Merck, and Lonza, joins host David Brühlmann to reveal the inside story on when and why you might want to look beyond traditional Western manufacturing partners.Here are three key insights from their conversation:The Post-Pandemic Manufacturing Revelation: "During the pandemic, we realized how vulnerable our supply chain truly is," explains Abdelaziz. Discover why diversifying manufacturing partnerships isn't just smart—it's becoming essential for resilience in an unpredictable world.Beyond the Cost Advantage: While Indian CDMOs can deliver up to 80% cost savings compared to Western counterparts, Abdelaziz reveals the unexpected advantages that make the most strategic partnerships about far more than budget considerations.The Trust Factor: "This is a business of trust," emphasizes Abdelaziz. Learn the critical questions that separate world-class Indian CDMOs from the rest, and the cultural nuances that can make or break your manufacturing partnership.Ready to discover if Indian CDMOs could be the missing piece in your biologics development strategy? Tune in for expert insights on IP protection, talent access, and how to navigate the cultural dynamics that determine success in this emerging manufacturing powerhouse.Listen to the full episode to unlock the strategic advantage that could transform your pipeline's journey from lab to market.Want to find out more about the CDMO selection? Here's what one of our distinguished guests had to say about it:Episodes 103-104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma MostafaConnect with Abdelaziz Toumi:LinkedIn: www.linkedin.com/in/abdelaziztoumiLupin Manufacturing Solutions: www.lupin.comNext step:Transform your process development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/callReady to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Im Kanton Graubünden geht es vorwärts mit dem «Solarexpress», Visp VS boomt dank Lonza, Kanton Solothurn: Hundesteuer kommt vors Volk

Nadja Studer - Direktorin - Kultur und Kongresszentrum La Poste - Visp   Losät - losät - losät. Was für än tolle Hengert hä ich mit der Nadja chenu hä. Sie ist Direktorin im Kultur und Kongress Zentrum La Poste in Visp.  Aber sie ist nicht nur dies - nein sie ist : Ehefrau - Mutter - und ja ist in dem was Sie tut sehr fokussiert. Ob man sich mehr als zwei Ziele pro Tag setzen darf und wieso es eh anders kommt als man es geplant hat. Das erfahren wir hier und jetzt in diesem Blogbeitrag und schon bald im Walliser Podcast - Ische Hengert.    Wo fängt man an? Wie fängt Nadja den Tag an? Mal ein bisschen Ortsmarketing und dann mal schnell den Philipp Fankhauser anrufen? Nadja erzählt uns wie ihr Tag abläuft und wir erhalten sehr viel Hintergrund Infos aus ihrem doch sehr bewegten Alltag. Haben Sie gewusst, dass so eine Direktorin mit ihrem sehr guten und tollen Team schon einiges zu erledigen hat. Kommen Künster:innen / Schauspieler aus dem Ausland kümmert man sich um Quellensteuer, ein faires Einkommen, beste Rahmenbedingungen im La Post in Visp.   Sicherheit - sicher auch sein sehr wichtiges Thema damit auch keinem Schauspieler:in eine Lampe oder Lautsprecher auf den Kopf fällt. Dann auch ja Housekeeping-Hygiene-Nothelferkurs-Weiterbildungen-Fachtagungen mit Berufskollegen:inn u.v.m. Ein doch sehr abwechslungsreicher Job und warum auch da gute Walliser Gastrfreundschaft wichtig ist und wir schlussendlich ja dafür bekannt sind die Menschen gut und freundlich zu bewirten.    Genuss kommt in diesem Hengert auch vor ? Ja darf man ein Raclette über die Cholera streichen? Das wäre doch noch was und klar - ihr Lieblingswein ist der Heida aus Visperterminen welcher jeder Haushalt da direkt via Leitung eingespeist bekommt. Chabissss? Ich habe Nadja einen Wein der Kellerei de Canali mitgebracht - Neo Vino - der freinfruchtige Rosé von Marc-André Cina.    Neben eben Genuss nun auch Engagement Social und Umweltschutz und wieso Nadja sich aus dem Vereinsleben verabschiedet hat? Fokussnuss  und ja eben sicher war auch das Verzetteln ein Thema - sie und ihr Team welche ja so viele Aufgaben haben wie eben auch TECHNIK; das Restaurant und die ganzen Anlässe, Mitarbeiter, Löhne, Verantwortung, Offerten, AGB`s, Social Media, Ortsmarketing, Sponsoring, Abo`s verkaufen, Programm planen, Sitzungen und so viel mehr !!  Es geht auch um Frauen in Führungspositionen im Wallis und ja Stand der Dinge.    Dann haben wir noch folgendes besprochen - ein Fallbeispiel : Ehemann sehr sehr günstig abzugeben und wie müssten ich nun vorgehen um mein Theaterstück auf die Bühne vom - ins - ums - ans La Poste zu bringen? Mensch, das gibt ja noch einiges zu tun und kennen sie den Unterschied von zb einer Urauff¨ührung und einer Premiere.  All das und noch viel mehr erfahren sie ja wie schon gesagt im Walliser Podcast-Ische Hengert by Radio Supersaxo und wie geht es da weiter ? Es kommt der Super-Mai mit Events am 5.05 - am 15.5 und am 25.5 - Fendärboerg - Studio Supersaxo - das Buch.     Der nächste Podcast Gast = Walter Schwery von der Buchbinderei Schwery in Brig welches ja das Buch der Bücher drucken und binden tut. Dies in doch einer spannenden Auflage von NUR 22. Stück welche schon ab 222 CHF erhältlich ist. Dieses Projekt sowie das Projekt Studio Supersaxo - die musikalische Eventlocation samt Schreiblabor kann gerne unter www.lokalhelden.ch/supersaxo unterstützt werden.    Wir danke allen für die Unterstützung, fürs teilen, fürs KOMMUNZIZIEREN und kommentieren. Ihr seid die Besten. Danke u häbet Gott oder äu mal eifach nix for Äugäää?   Gruss u Dank   Godi Supersaxo www.radiosupersaxo.net

Laut Umweltorganisationen sind die Pläne der Lonza für die Dichtwand bei der Altlastendeponie Gamsenried nicht gut genug. Sie verzichten momentan aber auf eine Einsprache. Weiter die Sendungen: · Probleme bei Schifffahrtsgesellschaft auf dem Neuenburger- und Murtensee: Die Mitarbeitenden beklagen sich über schlechte Arbeitsbedingungen und die Firma schreibt rote Zahlen. · Thun bewirbt sich als Kulturhauptstadt 2030.

In knapp einem Jahr, finden im Kanton Bern Wahlen statt. Die SVP weiss noch nicht, wie viele Kandidaten sie aufstellen will. Wie reagiert der Rest der bürgelichen Parteien darauf? Weiter in der Sendung: · Verschiedene Umweltorganisationen kritisieren die Pläne der Lonza in der Altlastdeponie Gamsenried. · Ein Umweltbüro beschuldigt den Energiekonzern BKW den Umweltverträglichkeitsbericht für die Solaranlage Schattenhalb beschönigt zu haben. · Probleme bei Schifffahrtsgesellschaft auf dem Neuenburger- und Murtensee: Die Mitarbeitenden beklagen sich über schlechte Arbeitsbedingungen und die Firma schreibt rote Zahlen.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Ben Locwin, Chief Scientist, Head of Clinical Services and Project Sciences at Black Diamond Networks (BDN). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ben, covering: Being part of the Lonza growth story in its 'scrappy' years Learning never to say no to a good opportunity and how that's opened many doors Becoming part of the more significant patient conversations at Biogen Dropping in seal teams to help companies do what they may never have achieved Why is change always inevitable in our sector, and what may the future hold for us all? As the saying goes, we're all a product of our growth and past experiences. Ben Locwin is an industry and healthcare executive who has been variously described as a "Remarkably talented speaker" by the Association for Talent Development, a "Rockstar epidemiologist" by NPR, a "healthcare futurist" by Contract Pharma and Rodman Media, and "a good friend" by ...his friends. He began his journey as an astrophysicist 30 years ago and then transitioned into the world of biotech in the 1990s when the nascent industry was yet poised to take over the world. He has specialized training as a neuroscientist and has worked with some of the top companies in the industry, both as a leader and a consultant. He has been a member of several Boards, association committees, steering teams, Task Forces, and scientific advisory panels. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Text us your thoughts on the episode or the show!Curious about how a fitness instructor transitions into a marketing ops powerhouse? Join us for a fascinating conversation with Jannelle Roscoe, the Associate Director of Digital Marketing and Marketing Systems at Lonza. Jannelle shares her unique journey from the world of fitness to mastering marketing operations, all while sticking to a budget. Her experience highlights the importance of customer-centric thinking, not only when engaging with external clients but also within internal teams. Her insights into customer journeys and motivations are must-hear lessons for anyone navigating the complex realm of marketing operations.In our discussion, you'll discover the power of continuous learning and humility in professional growth. Jannelle opens up about embracing new challenges and overcoming the fear of not knowing everything, striking a perfect balance between confidence and humility. We explore the importance of creating nurturing environments where newcomers can freely ask questions, seek guidance, and grow without unnecessary struggles. This approach not only fosters personal growth but also strengthens the marketing operations community by encouraging collaboration and shared experiences.Episode Brought to You By MO Pros The #1 Community for Marketing Operations Professionals Find your next great hire in the MarketingOps.com community. Reach specific members seeking new opportunities by region, years of experience, platform experience, and more. Support the show

Sun, 02 Feb 2025 10:56:35 +0000 https://morningbull.podigee.io/1188-new-episode bbba750db027f10413cef7f6509f6b5c full Le point de situation sur les places de bourses mondiales, mais surtout en Suisse après une semaine spectaculaire sur la tech américaine. no Swiss Bliss,Swissquote,Bourse,Finance,Trump,DeepSeek,Roche,Novartis,Nestlé,Lonza,Logitech Thomas Veillet et Vincent Ganne vous proposent un tour d'horizon de to

In this podcast we speak to experts from Lonza and Oxford Nanopore about their collaboration to bring direct mRNA sequencing (including N1-Methyl-pseudouridine) to a regulated environment and establish the new gold standard in sequencing technology. We discuss how nanopore sequencing will be used to perform unbiased identity testing while enabling the simultaneous analyses of multiple critical quality attributes such as integrity (mRNA length and poly-A tail length) and capping.

Ist es ein Turm oder doch nicht? Der BIZ-Tower soll durch ein Hochhaus in nächster Nähe ergänzt werden. Das ikonische Lonza-Hochhaus bekommt dereinst gleich zwei neue Nachbargebäude. Die Frage nach dem Hochhaus hat die Basler Architekturwelt auch im Jahr 2024 beschäftigt. Aber nicht nur: beim Bauinspektorat scheint der Wurm drin. Lange Wartezeiten und Personalprobleme verursachen Ärger. Auch im Klybeck liefs nicht rund. Gibt es nun Schadstoffe auf dem Areal oder nicht? Die BVB möchte alle Wartehäuschen ersetzen. Im September wurde allerdings gegen einen Rückbau Einsprache erhoben. Ebenso gegen die Pläne, die Antoniuskirche mit PV-Zellen einzudecken. Von den Bestrebungen der Solaroffensive bis zum «Eiligen Geist» im Schönthal in Langenbruck. Zum Jahresbeginn diskutieren Lukas Gruntz und Simon Heiniger, was in architektonischer Hinsicht 2024 wichtig für Basel und Umgebung war und was uns auch 2025 beschäftigen wird. WEBSITE www.architekturbasel.ch INSTAGRAM www.instagram.com/architekturbasel FACEBOOK www.facebook.com/archibasel YOUTUBE www.youtube.com/channel/UC6hTXmiATFx-Pp6NodIBLvQ

Die Lonza und die Behörden haben eine Vereinbarung unterzeichnet. Gemäss dieser übernimmt das Pharmaunternehmen die Kosten für den Bau der Dichtwand. Die Wand ist Teil der ersten Etappe der Sanierung der Deponie und soll belastetes Grundwasser zurückhalten. Weiter in der Sendung: · Mehr Personal: Der Kanton Wallis finanziert dreissig neue Stellen in den Spitälern. · Ausgangssperre aufgehoben: Die Ausgangssperre für Jugendliche in Moosseedorf sei unzulässig, zu diesem Schluss kommt die Regierungsstatthalterin Ladina Kirchen. · 1.4 Milliarden Franken: Der Schuldenberg der Stadt Bern wächst weiter.

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden.  Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. 2024 ist das Jahr der unbekannten Billionäre. Broadcom ist jetzt auch einer. Ansonsten beweist die Münchener Rück mal wieder, dass Versicherungen nicht langweilig sind. Abseits davon werden Food-YouTuber und Konzerne für zig Millionen verkauft. Nokia (WKN: 870737) hat zwar kein iPhone und AT&T hat man auch verloren. Aber: Krankenhäuser, Flughäfen und das Militär brauchen 5G. Das ist die Zukunft. Nahrungsergänzungsmittel boomen und zig Firmen verdienen sich daran eine goldene Nase. Lonza (WKN: 928619) leider nicht. Aber der Rest läuft umso besser. Diesen Podcast vom 16.12.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Sat, 14 Dec 2024 11:31:19 +0000 https://morningbull.podigee.io/1144-new-episode 1a10a981ec74044de0d8dc991a2270b2 full Le points sur les marchés financiers mondiaux, les banques centrales et l'inflation. Le monde est en train de ralentir pour boucler l'année, mais reste la FED au bout du chemin. no Swiss Bliss,Swissquote,Bourse,Finance,Suisse,Feintool,Santhera,Roche,Lonza,Swiss RE,Inflation Thomas Veillet et Vincent Ganne vous proposent un tour d'horizon de toutes les class

Hanns-Christian Mahler, Chief Enablement Officer at ten23 health, is redefining leadership in pharmaceutical manufacturing: “I believe collaboration at the workplace should be primarily based on trust and motivation, not on typical carrot and stick command and control models.” Founded in 2021, ten23 health has a mission to be a human-centric and sustainable strategic partner of the pharmaceutical industry. With extensive experience at companies including Merck, Roche, and Lonza, Hanns-Christian brings a fresh perspective to the CDMO space, combining technical expertise with innovative leadership approaches. In the latest episode of the PharmaSource podcast, Hanns-Christian shared insights into how ten23 health is revolutionising the CDMO sector through three key pillars: expertise-driven services, human-centric leadership, and sustainable operations. The company's unique approach demonstrates how CDMOs can differentiate themselves in a competitive market while prioritising both people and planet. Read more Connect with ten23 health at CDMO Live 2025, 7-8th May 2025 at the World Trade Center, Rotterdam. Find out more about the event here

Die Kantonspolizei Bern hat eine Initiative zur Bekämpfung von Hassdelikten lanciert. Damit will sie insbesondere gegen die steigende Zahl von Delikten vorgehen, die aus antisemitischen und antimuslimischen Motiven begangen werden. Weiter in der Sendung: · Armeeunfall in Siders: Panzerhaubitze fällt beinahe vom Lastwagen. · 200 neue Arbeitsplätze: Lonza in Visp baut aus. · Brand: Bahn aufs Jungfraujoch steht still. · Busse für die Berner Young Boys: Weil beim Champions League-Spiel gegen Inter Mailand im YB-Fansektor Pyrotechnik gezündet wurde. · Das Ehepaar Nicole Loeb und Lorenz Furrer am MäntigApéro des Regionaljournals und der SRG Bern Freiburg Wallis – ein Best-Of.

We are back! Discover the latest in pharmaceutical innovation from CPHI Milan with A View On! This episode explores advancements in bioconjugates, AI-driven drug development, targeted capsule delivery, and new solutions in cell and gene therapy that are transforming patient care. Tune in to hear from Lonza experts on the future of pharma and biotech.

Um mehr hochwirksame Krebsmedikamente für einen Kunden herstellen zu können, muss das Biopharmaunternehmen Lonza ausbauen. Dies bedeutet auch 100 neue Stellen.  Weiter in der Sendung: * Wahlen Stadt Bern: Vorschau auf das Streitgespräch zwischen Ursina Anderegg vom Grünen Bündnis und Janosch Weyermann von der SVP. * Der EHC Biel verliert auswärts 2 zu 4 gegen die ZSC Lions und Freiburg-Gottéron gewinnt im Jura 3 zu 1 gegen Ajoie.

Joerg Ahlgrimm brings over two decades of experience in pharmaceutical manufacturing and operations to his role as Chief Executive Officer at SK pharmteco. His distinguished career includes leadership positions at Schering, Baxter, and Lonza, where he managed 35 facilities during a period of unprecedented growth. He was one of the founding members of the Center for Breakthrough Medicines (CBM), where he served as employee number four and helped build the operation from scratch before the CDMO was acquired by SK pharmteco. In this exclusive interview, Joerg shares insights into SK pharmteco's strategic vision, the future of pharmaceutical outsourcing, and why making outsourcing “easy” is crucial for success in the evolving CDMO landscape. His unique perspective comes from having experienced both sides of a major acquisition, overseeing the integration of CDM into SK pharmteco. Joerg Ahlgrimm, CEO of SK pharmteco, believes the CDMO industry is heading for significant consolidation: “If you fast forward 10 years, there will probably be 10-15 large, multi-modality CDMOs, with many smaller and specialised ones being bought.” Read the full article on PharmaSource

Part 4 of 4. My guest for this week's episode is Derek Hennecke, a veteran biotech entrepreneur and board member with over 30 years of experience in the CDMO industry, whose mission is to support the biotech revolution and create value for patients, customers, and investors. In addition to his Board work, Derek previously held leadership positions at DSM and was the Founder and CEO of Xcelience, a Florida-based CDMO specializing in preformulation, micronization, analytical services, formulation development, cGMP manufacturing, and more. Derek eventually sold Xcelience to Capsugel (now Lonza) in 2016. His extensive pharma and cell therapy expertise makes for an insightful conversation that founders can learn from.

Chaque année? le 10 août? c'est la journée mondiale du Lion. Au delà de sa majesté, BSG rend hommage à TOUS les félidés avec cet épisode spécial._______D'où viennent les noms des félins ? Le terme de félin nous provient du latin classique felis, traduit le plus souvent par “chat”, mais qui pouvait aussi désigner d'autres petits carnivores chasseurs de rongeurs, comme la genette, le putois ou la martre. Notons que le mot felis dérive lui-même de feles, à savoir “voleur” ! C'est dire la piètre estime des romains pour les chats !La passion pour les chats et autres félins s'appelle l'ailurophilie. Là, on doit regarder du côté du grec ancien et de son mot pour désigner le chat, aïlouros, qui signifie littéralement “animal à la queue qui remue”, référence à l'appendice caudal très expressif des félins. Latinisé en ailurus, on le retrouve dans le nom scientifique de nombreux petits félins. Concernant le tigre. Les grecs de l'Antiquité employaient déjà le terme de tigris, emprunté à un dialecte d'origine iranienne, mot repris ensuite en latin. Le terme a longtemps désigné non seulement notre tigre, mais à peu près tout félin de grande taille hors lion, comme le Puma ou le Jaguar dans le pays latinos !Le mot « lion » nous vient aussi du grec ancien, d'une racine signifiant “puissant”. Vient ensuite le léopard. On le pensait issu du croisement entre le lion et la femelle du “pard”. Ce gros félin esten tous cas capable de traîner un taureau sur 8m. Qui dit mieux ?Le mot “panthère” signifie “toute bête” ou “bête totale”, incompréhensible aujourd'hui …Enfin vient l'américain du lot : le jaguar. Les premiers européens à débarquer dans le Nouveau Monde l'ont appelé “tigre” (espagnol) ou “onça” (portugais), noms restés encore courants de nos jours. Son nom actuel proviendrait du tupi et signifie “celui qui tue d'un bond”.Les derniers grands félins, les moins imposants, sont les panthères nébuleuses, ou longibandes. Le mot “nébuleuse” vient du latin nebula, qui signifie “nuage”. Le terme longibande est lui peut-être une contraction de “longue bande”.  Le Jaguarondi, ou chat-loutre est plus petit. Court sur patte, il serait le seul félin à vivre en couple.L'Ocelot vient quant à lui du Nahualt "Ocelotl" et signifie... "'jaguar". Bon grimpeur, il est plus grand que le Margay, qui lui ressemble. L'Ocelot apparaît dans le Vieux qui lisait des romans d'amour, le beau roman du Chilien Luis Sepulveda, bien que l'animal tueur du roman ressemble plus au Jaguar... La Panthère des neige mérite bien de s'appeler “panthère” plutôt que “léopard”, même si les deux mots sont synonymes. Je l'avais raconté dans les épisodes dédiés au léopard d'Arabie. En Asie, les Léopards sont des “Panthères” et en Afrique, on préfère le terme “léopard”. En anglais, on dit d'ailleurs “snow leopard”.Mais elle s'appelle aussi “Once”, qui a une origine prodigieuse : “Once” vient du lynx Lonza en latin, qui a perdu son “l”. Celui qui a commis cette faute pensait que le “l” était l'article ! Les noms du vivant ont des origines fabuleuses, dont ce genre d'approximation et d'erreur. Je raconte les plus surprenantes, les plus magnifiques dans une conférence,  un livre et aussi chaque semaine dans le podcast Nomen. Last but not least, dans les pays en -stan, comme le Kazakhstan, on l'appelle”Irbis”, qui est son nom russe. ______On aime ce qui nous a émerveillé … et on protège ce qu'on aime.______ Découvrir tout l'univers Baleine sous Gravillon, et Mécaniques du Vivant sur France Culture :https://baleinesousgravillon.com/liens-2Soutenir notre travail, bénévole et sans pub :https://bit.ly/helloasso_donsUR_BSGhttp://bit.ly/Tipeee_BSGhttps://bit.ly/lien_magq_lilo_BSGNous contacter pour une conférence, un partenariat ou d'autres prestations ou synergies : contact@baleinesousgravillon.com

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über einen guten Tag für Pharma, den Höhenflug eines SpaceX-Konkurrenten und die Fortsetzung des Auto-Bebens. Außerdem geht es um Stellantis, Renault, Ford, General Motors, AMD, Qualcomm, Infineon, Nvidia, STMicroelectronics, Roche, Lonza, Sanofi, Abbvie, Viking Therapeutics, AST SpaceMobile, Thyssenkrupp, Alphabet, Microsoft, Coca Cola, Swiss Life, VAT, Munich Re, Allianz, Alphabet, Apple, L&G Russell 2000 US Small Cap Quality ETF (WKN: A0Q8H2). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Die Firma Lonza will zwei neue Türme, neben dem bisherigen Hochhaus bauen. Für 700 Arbeitsplätze und 200 Wohnungen.

Join Michelle Martin and Ryan Huang in a tour of markets in minutes! Dive into Hongkong Land's $1 billion revamp of Landmark Mall and its impact on stock performance. Explore the downturn in China's industrial parks affecting companies like Lonza. Discover Amazon's recent stock surge and Micron's mixed earnings report. Get updates on Novo Nordisk, Beyond Meats, and Levi's stock movements. Finally, hear about ValueMax's plans for a Malaysian listing and local market highlights with SingTel and SATS.See omnystudio.com/listener for privacy information.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Andy Holt, CCO of Viralgen Vector Core. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andy, covering: Growing a CDMO while dealmaking in a gene therapy company…at the same time Selling a revenue-generating therapy company to Bayer during the pandemic Faster failure or faster acceleration; the need to celebrate every gene therapy batch as it's going to save lives The challenges of manufacturing AAV gene therapies and why the next generation of CGT CDMOs need a voice at the table  Andy has been working on the business side of cell and gene therapy for more than 15 years, focused on creatively connecting science and solutions, whether health care for whale sharks or supporting multi-billion dollar transactions between biotech and big pharma.  Along the way, he has held positions in business development and management for several large CDMOs like Lonza and MilliporeSigma, leadership positions in Askbio, Ncardia, and Cellistic, and his current role as Chief Commercial Officer for Viralgen, a pioneering AAV-focused CDMO leveraging Askbio's manufacturing expertise for clients around the world. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

Tune in to episode 233 of Momenta's Industrial Impact podcast for an exclusive interview with Dr. Alessandro Butté, CEO of DataHow. Explore the journey of DataHow, insights into AI model-based bioprocessing, Dr. Butté's expertise in Quality by Design at Lonza, and the impact of Momenta's Series A funding. Get ready for a glimpse into future trends in bioprocessing and AI integration.

Tracing the Evolution and Future of Capsule Manufacturing   In this episode, we are joined by Ljiljana Palangetic, Associate Director of Hard Capsules R&D, and Bram Baert, Senior Director of Regulatory Affairs from Lonza, to delve into the intricacies of capsule manufacturing and the evolution of drug delivery technologies.  Your grandmother might have told you to “just swallow your medicine,” suggesting that you may have to endure something unpleasant but necessary. Today, however, this old saying might not ring true, as capsules have become ubiquitous in modern medicine. Favored by 44% of consumers, capsules simplify medication intake with their ease of swallowing and ability to mask unpleasant tastes. From ancient Egyptian leather pouches to modern high-tech production lines, capsules have undergone significant transformations, seamlessly integrating into our daily lives. Swallowing one's medicine has never been so easy.   Yet the role of capsules has expanded far beyond taste masking. Today, they are engineered to deliver drugs to specific parts of the intestine, dissolve at controlled rates, and even contain multiple medications in one unit. This adaptability not only improves patient compliance but also caters to a myriad of medical needs. As we look toward the future, the potential for capsules in drug delivery is boundless, driven by continuous innovation and a deep understanding of materials science.  As mentioned in the podcast, if you haven't already listened to episode 9 of this season, you can find out more about targeted drug delivery using capsules here.    Curious to Know More?  Join us in this conversation hosted by Martina Hestericova with Lonza's Ljiljana Palangetic and Bram Baert as they unveil the advancements in capsule manufacturing technologies and their impact on modern drug delivery systems.    KEY TERMS IN CONTEXT:  Regulatory Affairs are crucial for ensuring that all pharmaceutical products, including capsules, adhere to legal and regulatory standards. Professionals in regulatory affairs navigate the complex landscape of pharmaceutical manufacturing, particularly focusing on consumer and patient safety, by collaborating with health authorities to establish and update regulations that ensure the safety and efficacy of capsules.  Two-piece Capsules consist of a cap and a body that fit together, making them a versatile choice for different types of medication delivery. The design innovations of two-piece capsules have evolved significantly since their inception in the mid-19th century. They accommodate a multitude of materials such as powders or granules and playing a crucial role in modern automated manufacturing processes.  Designed to pass through the stomach intact and dissolve in the intestines, enteric capsules are crucial for drugs that can be deactivated by stomach acid or may cause irritation to the stomach lining. This technology ensures that medication is released in the part of the gastrointestinal tract where its absorption is optimized, thereby enhancing both the drug's effectiveness and patient comfort.  The use of polymer solutions is integral to forming the shells of capsules, particularly in technologies where a capsule is dipped into the solution, allowing the polymer to dry and harden. The choice of polymer affects the capsule's dissolution rate and stability, which is critical for ensuring that the drug is released at the correct rate and location in the body.  Made from thin membranes derived from the small intestines of sheep, SAPARIS capsules are an early form of specialized drug delivery technology. They were designed to allow for a slow dissolution rate, aiming to improve the timing of drug release within the body. This technology showcases the evolution of capsule materials from organic origins to today's synthetic and semi-synthetic materials used in capsule manufacturing. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.This week's Commercialization Weekly highlights Bristol Myers' success with a Kras drug trial, Astrazeneca's FDA approval for a rare disease drug acquired from Alexion, FDA approval for Akebia's anemia pill after a previous rejection, and Acorda's bankruptcy filing. The FDA is also set to make decisions on expanding the use of two multiple myeloma cell therapies, a top-selling medicine, and Pfizer's gene therapy work. Risant Health has launched after Kaiser closed the acquisition of Geisinger, with plans to acquire more nonprofits. Surescripts is reportedly exploring a sale, with a private equity buyer being a potential option.Genmab acquired ProfoundBio for $1.8 billion, joining the trend of increased M&A activity in the development of antibody-drug conjugates. Paragon's hub-and-spoke biotech model resulted in another reverse merger with Oruka Therapeutics going public. Diagonal has raised $128 million to develop more efficient 'activator' antibody drugs. A dementia-focused venture capital firm is exploring new brain drugs beyond anti-amyloid therapies. Roivant reported positive immune drug data and announced share buyback plans.Genmab recently acquired the company ProfoundBio for $1.8 billion, expanding its presence in the antibody-drug conjugate (ADC) space with a focus on gynecologic cancers and solid tumors. Meanwhile, Diagonal Therapeutics secured $128 million in funding for their unique approach to developing agonist antibodies for rare diseases. In other news, Vanda Pharmaceuticals received FDA approval for their antipsychotic drug Fanapt for bipolar disorder, while Eli Lilly's diabetes treatment Mounjaro will be in short supply due to high demand.The text discusses the impact of tensions in U.S.-China research and development (R&D) relations on the Chinese antibody-drug conjugate (ADC) investment boom. With the departure of Chinese biotech company Wuxi from Bio, concerns over national security implications of U.S.-China R&D relationships are growing. The text also mentions the appointment of a new CEO at Lonza and Avenzo's pursuit of a licensing strategy with a new $150 million investment. Overall, the biopharma industry is experiencing significant developments in drug development, mergers and acquisitions, and regulatory decisions. Stay updated with Healthcare Dive for more insights into healthcare trends and news.Thank you for tuning in to Pharma and Biotech daily. Stay informed!

WuXi AppTec was once again in the news this week, with speculation that the China-based biotech allegedly handed a U.S. client's intellectual property over to the Chinese government without consent. Meanwhile, Lonza's $1.2 billion buy of a Roche biologics plant in California—one of the world's largest biologics manufacturing facilities by volume—bodes well for the CDMO market, and BMS pulls ahead of Amgen in the race to bring a fully approved KRAS inhibitor to market for patients with certain types of non-small cell lung cancer, acing a confirmatory Phase III trial for Krazati.

Vistazo a Kering y al sector lujo, a Lonza, Bureau Veritas y Eutelsat con Alberto Roldán, consejero de Metagestión.

Gavin Samuels, M.D. found his work as an intensive care physician boring. After earning his M.D., he did that for a few years before moving into intensive care management roles. It wasn't until he left the hospital and entered biopharma that he found his footing, cutting his teeth in business development at places like Merck, Pfizer, Quark Pharma, and Teva. He even headed growth strategy at Lonza for a while. Now, he's Chief Business Officer and General Partner at CinRx Pharma, where a deep pipeline of early- to late-stage candidates keeps him on his dealmaking toes. Within minutes of our conversation, Dr. Sameuls' introspective reflections on biotech dealmaking and negotiations planted this episode firmly on the Business of Biotech podcast highlight reel. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Simulating the Journey of Oral Medications: A Leap Towards Personalized Medicine  In this episode, we are joined by Deanna Mudie, a senior principal engineer at Lonza, and John DiBella, president of PBPK & Cheminformatics at Simulations Plus, to discuss new techniques in enhancing the bioavailability of drugs.  When you swallow a pill, have you ever pondered the intricate journey it undertakes to deliver its therapeutic effect? This voyage, crucial for the drug's effectiveness, is at the heart of pharmaceutical R&D's quest to enhance bioavailability - the proportion of the drug that enters circulation and reaches the target area.  By simulating how drugs interact with the body, scientists can optimize therapeutic outcomes by tailoring medications to the needs of individual patients. This approach promises a future where drugs are not only more effective but also safer, with reduced side effects. Listen as we delve into the cutting-edge world of Physiologically Based Pharmacokinetic (PBPK) modeling. These computer models integrate factors like gastrointestinal physiology and population characteristics, shedding light on how drugs behave in various body systems without the need for extensive patient testing.   Curious to Know More?  Join us in this conversation hosted by Martina Hestericová with Lonza's Deanna Mudie and Simulations Plus's John DiBella as they unveil the potential of PBPK modeling to revolutionize drug development and personalized medicine.     KEY TERMS IN CONTEXT:  In the context of pharmaceuticals, drug bioavailability refers to the proportion of a drug that enters the circulation when introduced into the body and is thereby able to have an active effect. It's a critical factor in determining the drug's effectiveness, as it measures how much of a drug in a dosage form (like a tablet or injection) becomes available at the target site of action.  PBPK modeling is a sophisticated computational modeling technique used to predict the absorption, distribution, metabolism, and excretion (ADME) of drugs within animals and humans. This approach aids in understanding a drug's bioavailability and supports the design of more effective and safer drug therapies.  Gastrointestinal Physiology refers to the study of the functions and processes of the digestive system or gastrointestinal (GI) tract. In the context of PBPK modeling, understanding gastrointestinal physiology is crucial for predicting how a drug is absorbed into the body, especially for orally administered medications. It includes factors like stomach acid levels, GI transit time, and the surface area available for absorption.  "In silico" refers to the use of computer simulations or digital analyses to conduct experiments or procedures virtually rather than in a laboratory or real-world setting. In silico tools in drug development include software and algorithms used for modeling and simulation, such as PBPK models, which allow researchers to predict how drugs interact with animals and humans, aiding in drug design, testing, and the customization of therapies for personalized medicine. 

APAC stocks failed to sustain the broad positive momentum from Wall St with the region mostly lower in quietened conditions and amid a lack of fresh drivers.Tokyo inflation data showed the slowest pace of core inflation in Japan's capital area since March 2022.FX markets are contained with the DXY sitting just above the 103.50 mark, USD/JPY was indecisive post-Tokyo CPI.European equity futures indicate a flat open with Euro Stoxx 50 future unchanged after the cash market closed up 0.4% on Thursday.Looking ahead, highlights include EZ M3, US PCE, ECB Survey of Professional Forecasters, Earnings from Volvo, Remy Cointreau, Lonza & American Express.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Capsules for Targeted Therapy: A Game-Changer in Modern Medicine  In this episode we are joined by Vincent Jannin, Lonza's R&D Director, to explore Enprotect, the Award-Nominated Capsule Technology.  Imagine starting your day with a simple capsule that goes beyond simply dissolving in your stomach to reach the place in your body where it is needed most before releasing its medicine. That's just what Lonza's Enprotect enteric capsules do. They are designed to release medication directly into the small intestine, which represents a significant leap in pharmaceutical delivery. They improve patient compliance without increasing production costs and offer targeted delivery for specific therapies such as live biotherapeutic products. This targeted approach is crucial for treatments that require local delivery, for example for Crohn's disease, exocrine pancreatic insufficiency, or Clostridium difficile infection.    In this episode we hear from Vincent Jannin about how advances in polymer science have ushered in this new era of capsules capable of targeted drug delivery. This marvel of modern medicine combines the fields of chemistry, nanoscience, biology, and physics. The creation of a bilayer capsule—comprised of a structural layer for shape and a functional layer for targeted release—both required the development of new technologies and could itself serve as an enabling technology for future therapies.    Vincent Jannin and his team have published several peer-reviewed studies in open access scientific journals, which were mentioned in the podcast:  In Vivo Evaluation of a Gastro-Resistant Enprotect Capsule under Postprandial Conditions (https://www.mdpi.com/1999-4923/15/11/2576)  In Vivo Evaluation of a Gastro-Resistant HPMC-Based “Next Generation Enteric” Capsule (https://www.mdpi.com/1999-4923/14/10/1999)  In vitro evaluation of the gastrointestinal delivery of acid-sensitive pancrelipase in a next generation enteric capsule using an exocrine pancreatic insufficiency disease model (https://www.sciencedirect.com/science/article/pii/S0378517322009966)  Curious to Know More?  Join us this episode as we explore the journey from a simple capsule to a sophisticated drug delivery system and how this advancement reflects a remarkable fusion of science and innovation. Discover how the Enprotect technology not only offers hope for more effective treatments but also exemplifies the relentless pursuit of medical advancement for the benefit of patients everywhere.     KEY TERMS IN CONTEXT:  An enteric capsule is a type of capsule specifically designed to bypass the acidic environment of the stomach and release its contents into the small intestine. The term 'enteric' relates to the small intestine. These capsules are formulated to remain intact in the stomach and dissolve only when they reach the more neutral pH levels of the intestine, ensuring targeted drug delivery.  Enteric polymers are materials used in the construction of enteric capsules. They are chosen for their ability to withstand acidic conditions (like those in the stomach) and dissolve at higher pH levels like those found in the small intestine. HPMC Acetate Succinate is an example of an enteric polymer used for the outer layer of the capsule to ensure the treatment's proper dissolution and release in the intestine.  Live Biotherapeutics (LBPs) refer to live microorganisms used for therapeutic purposes. They are designed to interact with the human microbiome, particularly in the small intestine, and are sensitive to stomach environments. The protection LBPs need before their release in the desired intestinal location is facilitated by specialized capsules.  Fecal Material Transfer refers to a medical treatment involving the transfer of fecal matter from a healthy donor to a patient, often used for conditions like Clostridium difficile infections. The podcast highlighted the potential use of enteric capsules for the delivery of such treatments directly to the small intestine, thereby offering an alternative to more invasive procedures. 

Die UBS-Aktie hat 2023 von allen SMI-Titeln am meisten zugelegt: plus 51.7 Prozent. Matthias Geissbühler, Anlagechef von Raiffeisen Schweiz, sieht den Grund dafür in der CS-Übernahme. Zu den Verlierern zählen Lonza und Roche. Nach dem Ende der Corona-Pandemie haben sie stark an Umsatz eingebüsst. SMI: + 0.7%

In this dramatic episode, Achim Nowak, Founder and President of BRILLIANT BEST, shares how he helps successful leaders embrace their fourth act and all the joy that it brings.You will discover:- What to do when you're done and ready to sell your business or retire from your career- How do develop a new vision for the months and years ahead- Why you may not need bigger goals, and what you do need instead
Achim Nowak helps CEOs and C-Suite leaders around the world to show up with relaxed authority and amplify their impact. His clients include global enterprises such as Sanofi, Takeda, Owens Corning, HSBC Bank, Lonza, Assurant, Welbilt, Dover Corporation and Chart Industries. He is a TEDx speaker, the author of 3 books on Personal Presence, host of the MY FOURTH ACT Podcast, and has been featured in The New York Times, The Wall Street Journal, USA Today, Fast Company, Forbes, Entrepreneur, MindBodyGreen and on NBC and NPR. He has an M.A. in Organizational Psychology and International Relations from New York University.
Want to learn more about Achim Nowak 's work at BRILLIANT BEST? Check out his website at https://achimnowak.com/

DOES YOUR COMPANY HAVE A MENOPAUSE PLAN?   Worldwide Menopause day went by last month and I - like most men I suspect - totally did not know about it(!). And yet menopause is an inherent and potentially significant moment in women's lives, one which is under discussed in society at large and certainly in the world of work. Does your company have a plan for menopause? If you have women in your workforce, you had better.   You will learn: Basics: - What is menopause, who is affected, when does it happen? - What are stages of menopause? - How does menopause manifest? - What can women expect to experience during menopause? - How long does menopause last? - What do we think of the recommended medical advice? - What is the state of menopause in the workplace? - What can employers do to normalise menopause, whilst also helping employees who may need extra help? - How can other employees assist? - What kind of work configurations, work designs should be considered? All this and more as we dive into a critically important yet neglected topic in the workplace. We're with Angela Cripps, MD, (Recruiting Gym), Kellie Millar, Recruitment Manager (Space & Time), Sally Higham, Head of Talent Attraction, (Lonza), Clair Bush, Founder (CareerSix), Lou Furby, Senior Events & Communications Manager (SpecSavers), Marisa Esteves, Manager, Talent Acquisition, (ScribeAmerica) & Jennifer Candee, Global Director of Talent Acquisition (Cargill)   Ep234 is sponsored by our buddies Poetry "This is a blueprint for improving our talent acquisition maturity." TA Leader, Engineering Poetry is a recruiter workspace including solutions for recruitment marketing, recruitment operations, recruiter learning and a launchpad for all the other tools you need to accomplish your daily tasks. We enable recruiters to be better marketers through enhanced collaboration, genAI assistance and automatic recommendations. These are the days of brilliant content. Gone are the days of re-writing InMails, social media posts and email copy. We save you considerable 'toggle tax' by providing so many solutions within the one app. Rapidly locate your job ad templates, competitor intelligence, interview policies and TikTok sourcing tools. Everything's in the one place. Managers, this is for you too. Our workspace analysis and reporting tells you how the team are using the solutions and provides you with automatic coaching, recommendations and ROI. Get started for free at www.poetryhr.com

Chaque année, le 23 octobre, c'est la journée mondiale de la Panthère des neiges. Ce hors-série inédit lui est dédié. Il n'en reste plus que 5000 en tout, dont la moitié en Chine. C'est moins que le nombre d'habitants à Dieulouard, le petit village lorrain où j'ai grandi, près de Nancy. La Panthère des neiges est parfaitement bien adaptée à son habitat de haute montagne, dans le froid glacé. Ce fantôme furtif parcourt son territoire, entre 2500 et 6000 m, dans les hautes prairies en été, et dans les rares forêts de conifères en hiver.   Son aire de répartition s'étend sur 12 pays. De la Chine à la Mongolie, en passant par le Népal, le Pakistan, et les pays du Caucase, dont les noms finissent en -stan. C'est vaste : autour de 2 millions de km², 4 fois la France. L'écrivain-voyageur Sylvain Tesson a contribué à la renommée de cet animal à la gueule d'ange. Son livre, sorti en 2019, a été adapté en documentaire en 2021. L'histoire se passe sur  le plateau du Changtang, au Tibet. Sylvain Tesson part avec le photographe animalier Vincent Munier, la réalisatrice Marie Amiguet et Léo-Pol Jacquot, à la recherche de cette reine de l'Himalaya, non loin des sources du fleuve Mékong. La Panthère des neige mérite bien de s'appeler “panthère” plutôt que “léopard”, même si les deux mots sont synonymes. Je l'avais raconté dans les épisodes dédiés au léopard d'Arabie. En Asie, les Léopards sont des “Panthères” et en Afrique, on préfère le terme “léopard”. En anglais, on dit d'ailleurs “snow leopard”. Mais elle s'appelle aussi “Once”, qui a une origine prodigieuse : “Once” vient du lynx Lonza en latin, qui a perdu son “l”. Celui qui a commis cette faute pensait que le “l” était l'article ! Les noms du vivant ont des origines fabuleuses, dont ce genre d'approximation et d'erreur. Je raconte les plus surprenantes, les plus magnifiques dans une conférence,  un livre et aussi chaque semaine dans le podcast Nomen. Last but not least, dans les pays en -stan, comme le Kazakhstan, on l'appelle”Irbis”, qui est son nom russe.  Son nom scientifique est intéressant lui aussi. Jusqu'en 2017, la Panthère des neiges s'appelait uncia uncia, elle était même la seule de son genre. Mais la génétique l'a fait revenir dans le giron des Panthérinés (les grands félins par opposition aux petits félins comme le Chat, le Puma et le Lynx regroupés dans les félinés), aux côtés du Lion (Panthera leo) du Tigre (Panthera tigris) du Jaguar (Panthera onca) et du Léopard (Panthera pardus). Aujourd'hui, elle s'appelle Panthera uncia. Elle a longtemps été classée dans un genre à part parce que contrairement à ses grands cousins panthérinés, elle ne rugit pas ! Et c'est dû à l'ossification partielle de l'os hyoïde, ce petit os de la gorge. Quand il est mou comme chez le lion et le tigre, l'animal peut rugir. Mais quand il est trop dur, ossifié, il ne peuvent que miauler, comme les Chats et les Lynx … C'est fou a quoi ça tient parfois la systématique ! ______ On aime ce qui nous a émerveillé … et on protège ce qu'on aime. ______ Découvrir tout l'univers Baleine sous Gravillon, et Mécaniques du Vivant sur France Culture : https://baleinesousgravillon.com/liens-2 Soutenir notre travail, bénévole et sans pub : https://bit.ly/helloasso_donsUR_BSG http://bit.ly/Tipeee_BSG https://bit.ly/lien_magq_lilo_BSG Nous contacter pour une conférence, un partenariat ou d'autres prestations ou synergies : contact@baleinesousgravillon.com ________ Interview : Marc Mortelmans Rédaction en chef des articles du site https://baleinesousgravillon.com : Guillaume Lassalle et Bérénice Toutant Rédacteurs : Julien Brethiot, Chloé Routa, Héloïse Caraty, Thomas Prat, Aurore Fayard, Rémi Trivellato BSG dans les Festivals : François Léger BSG sur Instagram : Audrey Tindilière Graphisme / vidéos : Elouan Plessix Montage / notices / programmation : Zeynab Tamoukh, Albane Couterot, Laure Davoigneau, Dorian Roulet

Chaque année, le 23 octobre, c'est la journée mondiale de la Panthère des neiges. Ce hors-série inédit lui est dédié. Il n'en reste plus que 5000 en tout, dont la moitié en Chine. C'est moins que le nombre d'habitants à Dieulouard, le petit village lorrain où j'ai grandi, près de Nancy. La Panthère des neiges est parfaitement bien adaptée à son habitat de haute montagne, dans le froid glacé. Ce fantôme furtif parcourt son territoire, entre 2500 et 6000 m, dans les hautes prairies en été, et dans les rares forêts de conifères en hiver.   Son aire de répartition s'étend sur 12 pays. De la Chine à la Mongolie, en passant par le Népal, le Pakistan, et les pays du Caucase, dont les noms finissent en -stan. C'est vaste : autour de 2 millions de km², 4 fois la France. L'écrivain-voyageur Sylvain Tesson a contribué à la renommée de cet animal à la gueule d'ange. Son livre, sorti en 2019, a été adapté en documentaire en 2021. L'histoire se passe sur  le plateau du Changtang, au Tibet. Sylvain Tesson part avec le photographe animalier Vincent Munier, la réalisatrice Marie Amiguet et Léo-Pol Jacquot, à la recherche de cette reine de l'Himalaya, non loin des sources du fleuve Mékong. La Panthère des neige mérite bien de s'appeler “panthère” plutôt que “léopard”, même si les deux mots sont synonymes. Je l'avais raconté dans les épisodes dédiés au léopard d'Arabie. En Asie, les Léopards sont des “Panthères” et en Afrique, on préfère le terme “léopard”. En anglais, on dit d'ailleurs “snow leopard”. Mais elle s'appelle aussi “Once”, qui a une origine prodigieuse : “Once” vient du lynx Lonza en latin, qui a perdu son “l”. Celui qui a commis cette faute pensait que le “l” était l'article ! Les noms du vivant ont des origines fabuleuses, dont ce genre d'approximation et d'erreur. Je raconte les plus surprenantes, les plus magnifiques dans une conférence,  un livre et aussi chaque semaine dans le podcast Nomen. Last but not least, dans les pays en -stan, comme le Kazakhstan, on l'appelle”Irbis”, qui est son nom russe.  Son nom scientifique est intéressant lui aussi. Jusqu'en 2017, la Panthère des neiges s'appelait uncia uncia, elle était même la seule de son genre. Mais la génétique l'a fait revenir dans le giron des Panthérinés (les grands félins par opposition aux petits félins comme le Chat, le Puma et le Lynx regroupés dans les félinés), aux côtés du Lion (Panthera leo) du Tigre (Panthera tigris) du Jaguar (Panthera onca) et du Léopard (Panthera pardus). Aujourd'hui, elle s'appelle Panthera uncia. Elle a longtemps été classée dans un genre à part parce que contrairement à ses grands cousins panthérinés, elle ne rugit pas ! Et c'est dû à l'ossification partielle de l'os hyoïde, ce petit os de la gorge. Quand il est mou comme chez le lion et le tigre, l'animal peut rugir. Mais quand il est trop dur, ossifié, il ne peuvent que miauler, comme les Chats et les Lynx … C'est fou a quoi ça tient parfois la systématique ! ______ On aime ce qui nous a émerveillé … et on protège ce qu'on aime. ______ Découvrir tout l'univers Baleine sous Gravillon, et Mécaniques du Vivant sur France Culture : https://baleinesousgravillon.com/liens-2 Soutenir notre travail, bénévole et sans pub : https://bit.ly/helloasso_donsUR_BSG http://bit.ly/Tipeee_BSG https://bit.ly/lien_magq_lilo_BSG Nous contacter pour une conférence, un partenariat ou d'autres prestations ou synergies : contact@baleinesousgravillon.com ________ Interview : Marc Mortelmans Rédaction en chef des articles du site https://baleinesousgravillon.com : Guillaume Lassalle et Bérénice Toutant Rédacteurs : Julien Brethiot, Chloé Routa, Héloïse Caraty, Thomas Prat, Aurore Fayard, Rémi Trivellato BSG dans les Festivals : François Léger BSG sur Instagram : Audrey Tindilière Graphisme / vidéos : Elouan Plessix Montage / notices / programmation : Zeynab Tamoukh, Albane Couterot, Laure Davoigneau, Dorian Roulet

Chaque année, le 23 octobre, c'est la journée mondiale de la Panthère des neiges. Ce hors-série inédit lui est dédié. Il n'en reste plus que 5000 en tout, dont la moitié en Chine. C'est moins que le nombre d'habitants à Dieulouard, le petit village lorrain où j'ai grandi, près de Nancy. La Panthère des neiges est parfaitement bien adaptée à son habitat de haute montagne, dans le froid glacé. Ce fantôme furtif parcourt son territoire, entre 2500 et 6000 m, dans les hautes prairies en été, et dans les rares forêts de conifères en hiver.   Son aire de répartition s'étend sur 12 pays. De la Chine à la Mongolie, en passant par le Népal, le Pakistan, et les pays du Caucase, dont les noms finissent en -stan. C'est vaste : autour de 2 millions de km², 4 fois la France. L'écrivain-voyageur Sylvain Tesson a contribué à la renommée de cet animal à la gueule d'ange. Son livre, sorti en 2019, a été adapté en documentaire en 2021. L'histoire se passe sur  le plateau du Changtang, au Tibet. Sylvain Tesson part avec le photographe animalier Vincent Munier, la réalisatrice Marie Amiguet et Léo-Pol Jacquot, à la recherche de cette reine de l'Himalaya, non loin des sources du fleuve Mékong. La Panthère des neige mérite bien de s'appeler “panthère” plutôt que “léopard”, même si les deux mots sont synonymes. Je l'avais raconté dans les épisodes dédiés au léopard d'Arabie. En Asie, les Léopards sont des “Panthères” et en Afrique, on préfère le terme “léopard”. En anglais, on dit d'ailleurs “snow leopard”. Mais elle s'appelle aussi “Once”, qui a une origine prodigieuse : “Once” vient du lynx Lonza en latin, qui a perdu son “l”. Celui qui a commis cette faute pensait que le “l” était l'article ! Les noms du vivant ont des origines fabuleuses, dont ce genre d'approximation et d'erreur. Je raconte les plus surprenantes, les plus magnifiques dans une conférence,  un livre et aussi chaque semaine dans le podcast Nomen. Last but not least, dans les pays en -stan, comme le Kazakhstan, on l'appelle”Irbis”, qui est son nom russe.  Son nom scientifique est intéressant lui aussi. Jusqu'en 2017, la Panthère des neiges s'appelait uncia uncia, elle était même la seule de son genre. Mais la génétique l'a fait revenir dans le giron des Panthérinés (les grands félins par opposition aux petits félins comme le Chat, le Puma et le Lynx regroupés dans les félinés), aux côtés du Lion (Panthera leo) du Tigre (Panthera tigris) du Jaguar (Panthera onca) et du Léopard (Panthera pardus). Aujourd'hui, elle s'appelle Panthera uncia. Elle a longtemps été classée dans un genre à part parce que contrairement à ses grands cousins panthérinés, elle ne rugit pas ! Et c'est dû à l'ossification partielle de l'os hyoïde, ce petit os de la gorge. Quand il est mou comme chez le lion et le tigre, l'animal peut rugir. Mais quand il est trop dur, ossifié, il ne peuvent que miauler, comme les Chats et les Lynx … C'est fou a quoi ça tient parfois la systématique ! ______ On aime ce qui nous a émerveillé … et on protège ce qu'on aime. ______ Découvrir tout l'univers Baleine sous Gravillon, et Mécaniques du Vivant sur France Culture : https://baleinesousgravillon.com/liens-2 Soutenir notre travail, bénévole et sans pub : https://bit.ly/helloasso_donsUR_BSG http://bit.ly/Tipeee_BSG https://bit.ly/lien_magq_lilo_BSG Nous contacter pour une conférence, un partenariat ou d'autres prestations ou synergies : contact@baleinesousgravillon.com ________ Interview : Marc Mortelmans Rédaction en chef des articles du site https://baleinesousgravillon.com : Guillaume Lassalle et Bérénice Toutant Rédacteurs : Julien Brethiot, Chloé Routa, Héloïse Caraty, Thomas Prat, Aurore Fayard, Rémi Trivellato BSG dans les Festivals : François Léger BSG sur Instagram : Audrey Tindilière Graphisme / vidéos : Elouan Plessix Montage / notices / programmation : Zeynab Tamoukh, Albane Couterot, Laure Davoigneau, Dorian Roulet

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Nando Sommerfeldt über die erstaunliche Erfolgsgeschichte unseres Nachbarn Polen, Fälschungs-Wirbel um Ozempic und neuen Ärger um den Trump-Spac. Außerdem geht es um Birkenstock, Digital World Acquisition (DWAC), Dino Polski, CD Projekt, iShares MSCI Poland (WKN: A1H5UP), Expat Poland WIG20 (WKN: A2JAHA), Recursion, Lonza, Nvidia und Novartis. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with J.D. Mowery, President and Chief Executive Officer at KBI Biopharma. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with J.D., covering: The experience of bringing a product to market... and then many years later seeing that product used on his wife to help bring his sons into the world How bringing a commercial facility online for Genentech to impact thousands of patients compares to the ‘vain to vain', hospital-based, one-off patient CAR-T product for Juno Why the ethos of taking care of the person on your left and the person on your right helps with the scale-up of a multi-national global CDMO The emergence of a partnership-based, absorption business model between innovators and CDMOs in the wake of the shift in capital markets What the next generation CDMO will look like… J.D. is an accomplished leader with a distinguished reputation in the biopharma industry and proven expertise in guiding global innovators and contract development and manufacturing organizations (CDMOs) for nearly 25 years. Throughout his diverse career, J.D. has demonstrated strategic vision and the ability to drive all aspects of an organization, including operations, R&D, manufacturing, tech transfer, facility construction, business development, employee growth, and investor relations. He is an expert in diverse modalities, including small molecules, biologics, and cell and gene therapy. J.D. has held executive leadership positions as  Head of Operations at Lonza and Executive Vice President of U.S. Operations at AGC Biologics. He has also held influential roles at innovators, including Genentech, Celgene, and Juno, and most recently served as Chief Operating Officer at Treadwell Therapeutics. J.D. holds a Bachelor of Science from George Fox University and an MBA from Marylhurst University. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

Die USA und Iran haben sich auf einen Gefangenenaustausch geeinigt. Fünf US-Gefangene wurden freigelassen. Im Gegenzug begnadigten die USA fünf Iraner. Das sei jedoch kein Signal einer nachhaltigen Entspannung, erklärt Katharina Willinger, Iran-Korrespondentin der ARD. Weitere Themen: (06:06) Ein Abkommen unter Feinden (12:12) Ständerat beschliesst Änderungen im Mietrecht (16:46) Der Streit um das Restwasser in Kraftwerken (21:25) Libyens Trauma nach den Fluten (25:21) Erneuter Abgang bei Lonza (28:18) Ernüchterung bei UNO-Nachhaltigkeitsgipfel (33:22) Wie umgehen mit Syrien?

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with TJ Higley, CEO at Microsize. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with TJ, covering: The fast, easy, scalable, precise, and non-patent-protected benefits of micronization How a synergistic capability alliance led to the eventual sale of his business to Lonza Capsugel The risks and realities of being an entrepreneur acquiring an organization, and then the collective rewards by incentivizing a team How a ‘getting the band back together' call led to TJ taking back the site he once sold to create Microsize The importance of strategic partnerships and recognizing that you can't do everything yourself TJ joined Microsize in 2022 as CEO to lead the company into the next growth phase. TJ brings 25 years of experience in the pharmaceutical market, most uniquely as a former owner and executive leader of Powdersize, Inc., the original and first CMO focused on pharmaceutical micronization in the US. TJ led both the business development efforts and oversaw the site quality team during his tenure, culminating in the acquisition of the company by Capsugel in 2015 and the integration into Lonza in 2017. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.  

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Apples China Problem, Immobilienverkäufe bei Vonovia und Hafenfantasie bei HHLA. Außerdem geht es um Unicredit, Commerzbank, Hamburger Hafen, Deutsche Bank, C3.ai, UiPath, Gamestop, Apple, AMC Entertainment, Novo Nordisk, Eli Lilly, Amgen, Viking Therapeutics, West Pharma, Becton Dickinson, Lonza, Biontech, Gerresheimer, Stevanato, West Pharma, VanEck US Fallen Angel High Yield Bond ETF (WKN: A3EEYM), Vodafone, Rolls Royce, der Telecom Italia, Las Vegas Sands, Ford Motor, Under Armor, Seagate, Transocean, Macys und Delta Airlines. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

"A View On: CAR-T Cell Therapies" featuring Tamara Laskowski, Senior Director of Clinical Development in Personalized Medicine at Lonza, and Aya Jakobovits, CEO of Adicet Bio. Dive into the world of CAR-T cells, their therapeutic potential, and the future of cancer treatments.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Daniel Eckert über Lebenszeichen bei einer Gesundheitsaktie, den erbitterten Preiskrieg bei E-Autos und eine Insel der Stabilität mitten in Europa. Außerdem geht es um Merck KGaA, Brenntag, Mercedes-Benz, Porsche, VW, BMW, Telefonica Deutschland, Sixt, Citigroup, JPMorgan Chase, Wells Fargo, Blackrock, State Street, UnitedHealth Group, Nokia, Ericsson, Partners Group, Meta Platforms, Novartis, Roche, ABB, Richemont, Lonza, Zurich Group, Nestlé, Perrigo, Invesco FTSE All-World akkumulierend (WKN A3D7QX), Lyxor DJ Switzerland Titans 30 (WKN: ETF030), Xtrackers SLI (WKN DBX1AA) und DWS Aktien Schweiz LC (WKN: DWS0D). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jesse McCool, Co-Founder and CEO at Wheeler Bio. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jesse, covering: His journey from the Lonza bench to the boardroom as CEO of Cytovance CEO before becoming a founder Building a CDMO from a blank canvas via a pit stop of C19 testing What makes Oklahoma City an attractive place to do business with its mixed blend of life science, tech and biomanufacturing expertise How Wheeler's hub and spoke satellite business model and platform is changing the CDMO business model Jesse McCool is the Co-Founder and CEO of Wheeler Bio, an agile, small-batch biologics drug substance manufacturer focused on addressing unmet needs in the translational space. He has over 20 years of biologics development and manufacturing experience in biotech and CDMO environments. He previously held executive and technical positions at Cytovance Biologics, Lonza, Lallemand/Mascoma, Dartmouth, and Clean Harbors. He joined Cytovance Biologics in 2013 to build out and lead the process development organization. The company was acquired by Hepalink in 2015 after which he was named Director, Chief Technical Officer and eventually, Chief Executive Officer. Jesse left Hepalink following the successful HK IPO in 2020 ($500MM USD) to join OKC-based venture studio, Echo Investment Capital, as Entrepreneur-In-Residence. He co-founded and launched Wheeler Bio in 2021. He also serves on the Governor's Council for Workforce and Economic Development (State Commerce) and works on numerous workforce development initiatives in the biomanufacturing sector. Jesse earned a Ph.D. from the University of Massachusetts at Amherst and completed his postdoctoral work at Dartmouth (Hanover, NH) and Delft University of Technology (The Netherlands). In addition to his industry experience, Jesse is an established public speaker, researcher, and peer-reviewed journal author and contributor. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.